Pituitary Tumors Associated With Multiple Endocrine Neoplasia Syndromes

Author(s):  
Liliya Rostomyan ◽  
Adrian F. Daly ◽  
Albert Beckers
2021 ◽  
Vol 67 (6) ◽  
pp. 4-5
Author(s):  
Article Editorial

Galina A. Melnichenko is a famous Russian scientist-endocrinologist, one of the leading in the country, author and head of fundamental and applied research. G.A. Melnichenko is one of the leaders in creating a methodology for organizing the endocrinological service of the Russian Federation. Galina Melnichenko is one of the leading specialists in the Russian Federation in the study of diseases of the thyroid gland, hypothalamic-pituitary system, orphan endocrinopathies, adrenal pathology, multiple endocrine neoplasia syndromes.


1990 ◽  
Vol 68 (13) ◽  
pp. 669-672 ◽  
Author(s):  
L. Schaaf ◽  
M. Greschner ◽  
W. Geissler ◽  
B. Eckert ◽  
F. J. Seif ◽  
...  

2019 ◽  
Vol 104 (9) ◽  
pp. 3637-3646 ◽  
Author(s):  
Anja Frederiksen ◽  
Maria Rossing ◽  
Pernille Hermann ◽  
Charlotte Ejersted ◽  
Rajesh V Thakker ◽  
...  

Abstract Context The clinical phenotype of multiple endocrine neoplasia type 4 (MEN4) is undefined due to a limited number of published cases. Knowledge on disease manifestation in MEN4 is essential for developing prevention programs and treatment. Objective To expand current knowledge of the MEN4 phenotype including assessment of penetrance. Design This is a case report and a brief review of previously published MEN4 cases. Patients We report a large Danish family with multiple cases of endocrine tumors that segregated with a pathogenic variant in the CDKN1B gene. Main Outcome/Result The medical history of the proband included primary hyperparathyroidism and Cushing disease. Genetic analysis identified a pathogenic variant in CDKN1B (c.121_122delTT, p.Leu41Asnfs*83). Among the family members, another 12 individuals were identified as carriers of the same variant, which segregated with development of endocrine tumors. Hypercalcemia due to primary hyperparathyroidism occurred in all 13 of the available carriers of the genetic variant, and 4 patients also had functioning or nonfunctioning pituitary adenomas, whereas 1 patient had a metastatic neuroendocrine tumor (carcinoid). Loss-of-heterozygosity was detected in two of five parathyroid adenomas, supporting that CDKN1B acts as a tumor suppressor gene. Thirty cases representing 16 different CDKN1B variants have previously been reported, and these cases presented primarily with primary hyperparathyroidism and functioning and nonfunctioning pituitary tumors. Conclusion Hypercalcemia due to primary hyperparathyroidism and pituitary tumors are common in MEN4. Gastrointestinal neuroendocrine tumors appear to be less prevalent in MEN4 than in MEN1.


Sign in / Sign up

Export Citation Format

Share Document